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ABSTRACT 
There are many uncertainties regarding Cystic Fibrosis (CF) treatment. Recently, the first 
James Lind Alliance (JLA) Priority Setting Partnership (PSP) in CF was completed, 
bringing clinicians, patients and carers together to identify the Top 10 research priorities. 
Here we investigate how well the current clinical trials landscape reflects these priorities. 
Trials in CF were identified through searches of research databases (Pubmed, ANZCTR, 
EU clinical trials register, ClinicalTrials.gov and ISRCTN). Trials meeting inclusion criteria 
of registered intervention studies in CF published between 01.01 2016 to 11.09.2017 
were matched to the Top 10 priorities. We identified 259 trials, with 193 fulfilling the 
inclusion criteria. Only 63 (33%) of these matched one or more of the JLA priorities 
showing that current clinical trials poorly reflect the JLA Top 10. By increasing awareness 
of the Top 10 priorities, it is hoped that this will fuel future research in areas important 
to the CF community.  
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INTRODUCTION 
Knowledge of CF genetics has led to the development of many new therapies targeting 
CFTR dysfunction[1], however currently the majority of treatment for CF is aimed at 
treating downstream consequences of the CFTR defect. There are still many 
uncertainties regarding symptomatic CF treatment[2]. Conventional therapies for 
persistent airways infection are still required and yet we do not have definitive evidence 
to guide the choice of many routine treatments (such as airway clearance).  Through 
undertaking well-designed clinical trials, these treatment uncertainties could be 
answered. 
Clinical trials should focus on questions which are important to patients and clinicians; 
however, until now, research agendas have been determined by researchers choosing 
topics that are of personal interest or of interest to funders such as the Pharmaceutical 
Industry. The National Institute for Health Research (NIHR) in the UK supports and 
facilitates patient and public involvement in research [3]. The NIHR James Lind Alliance 
(JLA)[4] brings patients, carers and clinicians together in Priority Setting Partnerships 
(PSP) to agree on a prioritised 'Top 10' list of research questions, as a stimulus to future 
research. 
 
In January 2017, the first JLA PSP in CF was completed, giving a list of Top 10 research 
priorities for treatment of CF[5]. During the JLA PSP process all priorities were checked 
to make sure we did not already know the answer using a systematic review identifying 
evidence gaps in treatment decisions in CF[2]. To investigate how well the current 
clinical trials landscape reflects the JLA Top 10 priorities for CF, we matched current 
clinical trials in CF to the JLA Top 10 priorities. 
METHODS 
We carried out a systematic review to identify ongoing trials in CF, following a published 
study protocol[6]. Pubmed, Australian New Zealand Clinical Trials Registry (ANZCTR), EU 
clinical trials register, ClinicalTrials.gov and ISRCTN ('International Standard Randomised 
Controlled Trial Number'; however, this registry now includes more than just randomised 
controlled trials) were searched with strategy adapted for each database, as shown in 
Appendix A. Other studies were identified by emailing experts in the field (Appendix B).  
Search results were collated and duplicates excluded. Inclusion criteria were completed or 
registered intervention studies conducted with people diagnosed with CF and published in English 
between January 1, 2016 to September 11, 2017. Trials that did not meet the predetermined 
inclusion criteria were excluded (for full inclusion criteria see Appendix C).  Included 
studies were matched to one or more of the Top 10 priorities by first reviewer (IK) and 
recorded on a database then checked by second reviewer (NR) to ensure accuracy. A 
third reviewer (SS) was available should disagreements occur. 
 
RESULTS 
We identified 253 trials through the database searches and an additional six studies 
through contact with study investigators. After removal of duplicates, this gave 252 trials 
for filtering of which 193 studies fulfilled the inclusion criteria and 59 were excluded. Figure 
1 shows a Prisma flow diagram of the study selection process. 
 
Figure 1. Prisma flow diagram of study selection process  
 
Only 63 of 193 trials (33%) matched one or more of the Top 10 priorities. The number of 
ongoing trials matching each priority varied widely. There were only two studies 
addressing priority 3, treatment of lung infection due to non-tuberculous mycobacteria 
(NTM) – an antibiotic resistant infection which causes severe lung damage. In contrast, 
there were 25 studies linked to priority 6, adherence to treatment. See Table 1. 
Appendix D gives a full list of trial titles and the priorities they were matched to. 
Priority question Number of trials matching 
1. What are the effective ways of simplifying the treatment burden of 
people with Cystic Fibrosis? 10 
2. How can we relieve gastro-intestinal symptoms, such as stomach 
pain, bloating and nausea in people with Cystic Fibrosis? 3 
3. What is the best treatment for non-tuberculous mycobacterium 
(NTM) in people with Cystic Fibrosis (including when to start and what 
medication)? 
2 
4. Which therapies are effective in delaying or preventing progression 
of lung disease in early life in people with Cystic Fibrosis? 4 
5. Is there a way of preventing Cystic Fibrosis related diabetes in 
people with Cystic Fibrosis? 7 
6. What effective ways of motivation, support and technologies help 
people with Cystic Fibrosis improve and sustain adherence to 
treatment? 
25 
7. Can exercise replace chest physiotherapy for people with Cystic 
Fibrosis? 2 
8. Which antibiotic combinations and dosing plans should be used for 
Cystic Fibrosis exacerbations and should antibiotic combinations be 
rotated? 
6 
9. Is there a way of reducing the negative effects of antibiotics e.g., 
resistance risk and adverse symptoms in people with Cystic Fibrosis? 3 
10. What is the best way of eradicating Pseudomonas aeruginosa in 
people with Cystic Fibrosis? 8 
Table 1.The number of clinical trials matching to each of the Top 10 priorities. 
Priority questions are in the number order they were ranked during the JLA PSP. Some 
trials were matched to more than one priority. 
All five of the clinical trials identified through contact with study investigators matched to 
Priority 6 (“What effective ways of motivation, support and technologies help people with 
cystic fibrosis improve and sustain adherence to treatment.”) 
DISCUSSION 
This study found that a very high proportion (67%) of the current trials in CF do not 
match any of the James Lind Top 10 priorities. This indicates a mismatch between the 
current clinical trials landscape and the priorities of the CF community. The James Lind 
top 10 priorities were derived from engagement with participants throughout the world 
and informed by a systematic review of existing gaps in the published research literature 
and so it is disappointing that ongoing research will not fill these gaps at present [2]. 
Our findings suggest a failure of the current arrangements for prioritising clinical trials. 
Similar studies in conditions other than CF also found a mismatch between their PSP 
priorities and trial landscape [8, 9, 10]. One study[8] identified the treatments described 
in prioritised research questions generated by the first 14 JLA PSPs and compared them 
to the treatments described in ongoing clinical trials over the same time period. The 
results highlighted that although the research of non-drug treatment was prioritised by 
the PSPs, the ongoing research mostly involved evaluations of drugs. Another study also 
found a mismatch between Top 10 priorities for Palliative and End of Life care and 
research in progress[11]. 
To date, there have been no studies that have investigated how well the current clinical 
trials landscape reflects the research priorities of the CF community.  
One of the most active areas of pharmaceutical research in CF is on modulators of the 
cystic fibrosis transmembrane conductance regulator (CFTR). Several CFTR modulators 
have received a marketing authorisation in recent years and many more are undergoing 
clinical trials. It is of interest that questions on CFTR modulators were absent from the 
Top 10. During discussions at the final workshop of the JLA PSP in CF, participating 
patients and clinicians said they believed that research regarding CFTR modulators will 
progress whether prioritised or not and so they did not propose them for the JLA top 10. 
The lack of ongoing trials in some JLA priority areas may be due to a lack of suitable 
interventions, which could be evaluated in a clinical trial (e.g. gastrointestinal problems 
or NTM). Increased awareness of the importance of these issues to the CF community 
may lead to discovery science, to understand disease mechanisms and suggest 
“druggable targets” or to trials of repurposed drugs. 
One strength of this study is the large number of current trials found in CF in countries 
worldwide, representing the current global clinical trial landscape in CF. Additional non-
database searches were used to find all current and relevant trials in CF. A matching check 
by a second reviewer was carried out to ensure accuracy. Reproducible methods were used 
to systematically search, match and analyse and were described allowing for the future 
accurate replication. These were then matched to the JLA top 10 priorities which were 
derived from engagement with participants throughout the world[5]. 
By identifying and highlighting the mismatches between the current clinical trials in CF 
and the JLA Top 10 priorities, we hope that researchers will be made aware that their 
agendas currently do not meet the priorities of the people who are in the greatest need 
of relevant research evidence. This is an important step towards “co-production” of 
research[3]. The research landscape is starting to change in response to the Top 10 with 
the NIHR supporting research based on the top 10 research priorities in CF. Using the 
methodology described in this study, further research could explore how future clinical 
trials in CF match to the priorities of the clinical and patient communities and how the 
Top 10 priorities for CF alter the research landscape further.  
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Appendix A: Search strategies used in the systematic review 
ClinicalTrials.gov 
Condition or disease: 'cystic fibrosis', Study Type: 'Interventional Studies', First posted: 
'01/01/2016' to '09/11/2017' 
ISRCTN 
Condition: 'cystic fibrosis', Date applied '01/01/2016' to '09/11/2017' and Overall trial 
start date '01/01/2016' to '09/11/2017' 
EU CLINICAL TRIALS REGISTER 
Search term 'cystic fibrosis', Date range '2016/01/01' to '2017/11/09' 
Pubmed 
'cystic fibrosis' in title/abstract, Date- Publication '2016/01/01' to '2017/11/09' 
Article types: 'Clinical trials' 
(cystic fibrosis[Title/Abstract]) AND ("2016/01/01"[Date - Publication] : 
"2017/11/09"[Date - Publication]) 
ANZCTR 
Search term 'cystic fibrosis', Study type: 'Interventional', Trial start date '01/01/2016' to 
'09/11/2017' and registration date '01/01/2016' to '09/11/2017' 
 
 
 
 
 
 
 
 
 
 
 
Appendix B: Experts contacted  
Additional studies were found by emailing experts in the field of research in CF who were 
asked if they were aware of any ongoing studies of interventions which might help 
address any of the Top 10 priorities. Responses were received from Aliza Fink and 
Alexandra Quittner and both provided information on the Success with Therapies 
Research Consortium (STRC). Through Aliza Fink, contact was made with Cindy George 
who leads the STRC at CFF who gave information regarding current studies run by the 
STRC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix C: Criteria for the inclusion of studies for the review 
 Inclusion criteria Exclusion criteria 
Types of study Interventional studies 
published in English. 
Studies published since 
01/01/16 to present and 
ongoing and also 
registered to take place 
trials. 
Qualitative studies/observational 
studies 
Participants Participants diagnosed 
with CF (through genetic 
testing or sweat testing) 
and of any age.  
Studies including other 
conditions but where CF 
patients were analysed as 
a specific subgroup were 
included if they met the 
rest of the inclusion 
criteria. 
Patients who are screen positive for 
CF but with no firm diagnosis 
Intervention Any treatment 
intervention actively 
involving participants with 
the potential to benefit 
participants directly.  
Studies involving trials of 
combinations of 
interventions, timings and 
duration of intervention 
and stopping 
interventions were 
included. 
The interventions were 
expected to fall into these 
categories: drugs 
interventions (antibiotics 
and CFTR modulators), 
behavioural interventions 
(supportive care etc), 
dietary interventions 
(vitamin D, fibre etc), 
device or web based 
interventions (trackers, 
smartphone apps or 
virtual reality etc) and 
other interventions such 
as home monitoring and 
exercise for example. 
Studies covering diagnosis, newborn 
screening or those concerning 
diagnostic test accuracy as well as 
those concerning policy, evaluation of 
the training of physicians or 
organisation of care.  
Interventions involving miRNAs 
isolation from blood samples, 
diagnostic tests, measurement of 
sputum rheological properties, 
measure of endothelial function etc 
Outcomes Any clinically meaningful 
outcome measure or 
those that reflected 
patient benefit.  
Those that did not reflect patient 
benefit ie studies aiming to assess 
outcome measures such as: 
bioavailability or pharmacokinetics, 
The outcomes were 
expected to fall into the 
categories listed: 
* Lung Function (e.g. 
FEV1,FVC, Lung clearance 
index etc) 
* Health-related quality of 
life validated measures 
(e.g. Cystic Fibrosis 
Questionnaire (CFQ) 26) 
* Respiratory symptom 
outcomes (e.g. 
Respiratory and Systemic 
Symptoms Questionnaire 
RSSQ) 
* Hospitalisation (e.g. 
number of nights 
inpatient) 
* School/Work attendance 
(e.g. number of days 
missed) 
* Nutrition & Growth (e.g. 
weight gain, height, fat) 
* Radiological (e.g. bone 
mineral density) 
* Sputum properties 
* Pulmonary 
exacerbations (measured 
by frequency of 
exacerbation or time to 
next exacerbation etc) 
* Antibiotic use (e.g. 
number of courses, 
combinations, delivery 
method) 
* Adverse effects (toxicity 
& allergy, microbiology, 
complication of delivery) 
* Exercise tolerance 
* Sweat chloride as a 
measure of CFTR function 
* Mucus clearance 
* Nasal symptom scores 
* Bowel symptoms (e.g. 
stool frequency, 
abdominal pain etc) 
* Treatment burden 
* Treatment adherence 
* Cost 
clearance, volume of distribution, 
DNA methylation etc 
 
 
Appendix D. Table showing trial titles and which research priority they matched with.  
References to clinical trials follow table. 
  DOES THE TRIAL MATCH ANY OF THE TOP 10 RESEARCH PRIORITIES? 
Trial Title 1 2 3 4 5 6 7 8 9 10 
1. Integrating Supportive Care in Cystic Fibrosis YES     YES     
2. Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis        YES   
3. Nutritional Intervention and Glycemic Improvement in Patients With Pre-diabetic Cystic Fibrosis.     YES      
4. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for 
the F508del-CFTR Mutation 
         YES 
5. A Study of Home Monitoring in Adults With Cystic Fibrosis (HOMECF) YES          
6. Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis          YES 
7. An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations   YES        
8. Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance     YES      
9. A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic 
Fibrosis, Homozygous for the F508del-CFTR Mutation 
   YES       
10. Simplification of CF-related Diabetes Screening at Home YES     YES     
11. Does exenatide improve post prandial glycaemic control in young people with cystic fibrosis 
related diabetes or impaired glucose tolerance? 
    YES      
12. The effect of low glucose load diet on glycaemic control in patients with cystic fibrosis     YES      
13. The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic 
Fibrosis 
    YES      
14. Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis Center      YES     
15. The Use of Home Oral Glucose Tolerance Test Kit in Screening Cystic Fibrosis Related Diabetes YES     YES     
16. Increase Tolerance for Exercise and Raise Activity Through Connectedness Trial      YES     
17. Improving Therapeutic Adherence With a Co-constructed Program Involving Both Patients and 
Health Care Professionals 
     YES     
18. Inhaled Nitric Oxide for Cystic Fibrosis Patients With MABSC   YES        
19. Saline Hypertonic in Preschoolers + CT    YES       
20. Impact of Telerehabilitation Training on Pediatric Cystic Fibrosis Patients: An Exploratory Study      YES     
21. A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic 
Fibrosis Exacerbations 
       YES   
22. Virtual Reality for the Reduction of Pain During Venipuncture in Children With CF      YES     
23. Virtual Care in CF (VIRTUAL-CF) Study      YES     
24. A CFit Study - Acute Exercise     YES      
25. Safety and Efficacy of 2 Treatment Regimens of Aztreonam for Inhalation Solution in Children 
With Cystic Fibrosis and New Onset Pseudomonas Aeruginosa Infection 
         YES 
26. Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis        YES YES  
27. Do More, B'More, Live Fit YES     YES     
28. IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy        YES   
29. A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure 
Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation 
     YES     
30. Standardized Treatment of Pulmonary Exacerbations II        YES   
31. Adherence to Airway Clearance. Novel Approaches to Improving Adherence      YES     
32. Project UPLIFT to Reduce Anxiety and Depression in CF Patients      YES     
33. SPI-1005 for Prevention and Treatment of Aminoglycoside Induced Ototoxicity         YES  
34. The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START): A randomised 
registry trial to assess the safety and efficacy of flucloxacillin as a longterm prophylaxis agent for 
infants with CF 
   YES       
35. Development and evaluation of an intervention to support Adherence to treatment in adults with 
cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and 
process evaluation 
     YES     
36. Randomised trial of a web-based intervention for adherence in cystic fibrosis      YES     
37. Effects of inhaled hypertonic saline in children with cystic fibrosis    YES       
38. Aztreonam for inhalation for the treatment of acute exacerbations in cystic fibrosis. An open-
label, randomised, cross-over pilot study of AZLI plus intravenous Colistin versus standard dual 
intravenous therapy. 
       YES   
39. Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP 
Administered BID in 28 Day on / 28 Day Off Cycles 
         YES 
40. A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study 
Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine 
Pancreatic Insufficiency 
 YES         
41. Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment 
Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation 
Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract 
Pseudomonas aeruginosa (PA) Infection/Colonization 
         YES 
42. An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Exocrine 
Pancreatic Insufficiency due to Cystic Fibrosis 
 YES         
43. Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis          YES 
44. A Phase 4, Open-label Treatment, Randomized, Multicenter, 2-arm, Parallelgroup, Pilot Study of 
Adherence to Lumacaftor/Ivacaftor in CF Subjects Homozygous for the F508del-CFTR Mutation 
     YES     
45. Combined Effect of CFTR Modifiers and Intensive Antibiotic Treatment          YES 
46. In adults with cystic fibrosis, what is the effect of a smartphone application used to report 
symptoms versus usual care on exacerbations requiring intravenous antibiotics, healthcare utilisation, 
lung function, quality of life, anxiety and depression, nutritional status, medication adherence and 
absenteeism and presenteeism. 
     YES     
47. Exercise alone versus exercise and positive expiratory pressure as a form of airway secretion 
clearance in adults with mild cystic fibrosis-related respiratory disease - a feasibility study YES 
     YES    
48. Musculoskeletal clinical  outcomes of Whole Body Vibration Training as an adjunct to 
physiotherapy in children with Cystic Fibrosis: a comparison of telehealth and face to face therapy 
delivery 
YES          
49. A randomised controlled trial of a novel web-based intervention to promote physical activity 
participation in young people with cystic fibrosis 
     YES     
50. CyFiT Telerehabilitation:  Investigation into the efficacy of a telehealth physiotherapy intervention 
on quality of life and community participation for school-aged children with cystic fibrosis, a 
randomised controlled trial 
YES     YES     
51. Effects of high intensity interval training on exercise capacity in people with cystic fibrosis: a 
randomised controlled trial YES 
         
52. Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary 
Exacerbations. eICE Study Results YES 
         
53. Effects of treadmill exercise versus Flutter® on respiratory flow and sputum properties in adults 
with cystic fibrosis: a randomised, controlled, cross-over trial. 
      YES    
54. Combined Exercise Training Improves Glycemic Control in Adult with Cystic Fibrosis     YES      
55. Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency 
due to Cystic Fibrosis: A Randomized Controlled Clinical Trial. 
 YES         
56. Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients 
with cystic fibrosis: a phase I clinical study. 
        YES  
57. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.          YES 
58. Web-Based Intervention for Nutritional Management in Cystic Fibrosis: Development, Usability, 
and Pilot Trial. 
     YES     
59. Standardized Measures of Barriers to Treatment Adherence      YES     
60. Design CF: Developing e-Health Systems to Improve Growth and Nutrition in CF      YES     
61. Video-Based Tele-coaching to Promote Treatment Adherence      YES     
62. A Mobile Medication Planning Application, MedActionPlan® (MAP), to Encourage Self-
Management      YES     
63. Chipped eTrack Devices to Collect Objective Measures of Adherence      YES     
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